Sample records for QUILOMICRONES (chylomicrons)
from WorldWideScience.org

Sample records 1 - 3 shown.



1

Ascitis quilosa: Presentación de un caso y revisión de la fisiopatología/ Chylous ascitis: Case presentation and review of pathophysiology

Jiménez, César Eduardo
2004-06-01

Resumen en español Se presenta un caso, manejado en la Clínica del Occidente de Bogotá, de un paciente masculino de 68 años con abdomen agudo, cuyos hallazgos en laparotomía exploratoria fueron ascitis quilosa. El sistema linfático está encargado de remover del cuerpo la pérdida de líquido del espacio intersticial, la absorción de triglicéridos en forma de quilomicrones y participa en el sistema inmune. La ascitis quilosa o quiloperitoneo, es una afección rara y poco reportada en (mas) la literatura, cuya incidencia ha aumentado por la mayor cantidad de cirugías para enfermedades neoplásicas en el tórax y abdomen que antes no se realizaban y la mayor longevidad de los pacientes en quienes se realizan. La ascitis quilosa se presenta por diferentes causas (postoperatoria, radioterapia, trauma, cáncer e idiopática, entre otras); tiene una mortalidad mayor del 20%, dada por los efectos deletéreos nutricionales e inmunológicos que produce. Su tratamiento se basa en nutrición parenteral y somatostatina. Resumen en inglés We report the case of a 68 year old man who presented to the Clínica de Occidente, Bogotá, Colombia, with acute abdomen and in whom exploratory laparotomy revealed chylous ascitis. The lymphatic system performs the task of draining fluid from the interstitial space, the absorption of tryglicerides in the form of chylomicrons; it also is part of the immune system. Chylous ascitis is a rare clinical entity that is seldom reported in the literature. Its incidence has incre (mas) ased, associated with the large number of thoracic operations that are performed today for malignant lesions and also with the greater longevity of the population. Chylous ascitis results from different causes (postoperative radiotherapy, trauma, cancer, idiopathic, and other). The mortality rate in over 20%, resulting from the deleterious nutritional and immunologic effects. Treatment is based on nutritional support and the administration of somatostatin.

Scientific Electronic Library Online (Spanish)

2

Utilidad y controversias del consumo de ácidos grasos de cadena media sobre el metabolismo lipoproteico y obesidad/ Usefulness and controversial issues of middle-chain fatty acids consumption on lipid-protein metabolism and obesity

Sáyago-Ayerdi, S. G.; Vaquero, M. P.; Schultz-Moreira, A.; Bastida, S.; Sánchez-Muniz, F. J.
2008-06-01

Resumen en español Los ácidos grasos de cadena media (AGCM) contienen entre 6 y 12 átomos de carbono y son digeridos, absorbidos y metabolizados de manera distinta que los ácidos grasos de cadena larga (AGCL). En este trabajo se revisan algunas de las utilidades potenciales y reales de los AGCM y su papel en la salud. Por ello, se utilizan en nutrición enteral y parenteral debido a la buena absorción que presentan; y en fórmulas lácteas en niños prematuros para mejorar la absorción (mas) de calcio. AGMC han cobrado un gran interés especialmente por su posible papel en el tratamiento y prevención de la obesidad. Al ser más hidrosolubles, no se incorporan a los quilomicrones y se acepta que no participan directamente en la lipogénesis. Son capaces de incrementar el efecto termogénico de los alimentos y en su metabolización elevan la formación de cuerpos cetónicos con el consiguiente efecto anorexígeno. No obstante, se requiere ingerir cantidades elevadas de AGCM para obtener efectos significativos en la reducción de peso. Los efectos sobre el metabolismo lipoproteico son controvertidos. Así, aunque parecen disminuir la respuesta trigliceridémica postprandial, los resultados no son uniformes respecto a sus efectos sobre la trigliceridemia y colesterolemia. A pesar de ello, se diseñan cada vez más productos en los que se incorporan grasas con AGCM para el tratamiento de la obesidad y sobrepeso, habiendo sido considerados por la ADA como componentes "GRAS" (Generally Recommended As Safe). Son necesarios estudios a más largo plazo para garantizar la utilidad del consumo de estos compuestos, particularmente en el tratamiento y prevención de obesidad. Resumen en inglés Middle-chain fatty acids (MCFA) contain 6-12 carbon atoms and are digested, absorbed and metabolized differently than long-chain fatty acids (LCFA). This work reviews some of the potential and real utilities of MCFA and their role on health. For this reason, they are used in enteral and parenteral nutrition because of their good absorption, and in premature-feeding milk-based formulas in order to improve calcium absorption. MCFA have become particularly important because (mas) of their possible role in treating and preventing obesity. Since they are more water soluble, they are taken-up by chylomicrons, and it is believed that they do not directly participate in lipogenesis. They are able to increase the thermogenic effect of foods, and its metabolism increases the production of ketonic agents with the subsequent anorexigenic effect. However, high doses of MCFA are required to obtain significant effects on weight reduction. The effects on lipid-protein metabolism are controversial. So, although they seem to reduce the post-prandial triglyceridemic response, the results their effects are not uniform regarding triglyceridemia and cholesterolemia. In spite of this, more and more products are being designed incorporating MCFA to treat obesity and overweight, having been considered as "GRAS" (Generally Recommended as Safe") components by the ADA. Further long-term studies are needed to warrant the usefulness of consumption of these compounds, particularly in the treatment and prevention of obesity.

Scientific Electronic Library Online (Spanish)

3

Heparina e insulina en el tratamiento de la pancreatitis aguda por hipertrigliceridemia: Experiencia en 5 casos/ Heparin and/or insulin treatment of acute pancreatitis caused by hypertriglyceridemia

Berger F, Zoltán; Quera P, Rodrigo; Poniachik T, Jaime; Oksenberg R, Danny; Guerrero P, Julia
2001-12-01

Resumen en inglés Background: Hypertriglyceridemia over 1,000 mg/dl can provoke acute pancreatitis and its persistence can worsen the clinical outcome. On the contrary, a rapid decrease in triglyceride level is beneficial. Plasmapheresis has been performed in some patients to remove chylomicrons from the circulation, while heparin and/or insulin have been administered in some other cases to rapidly reduce blood triglycerides. Heparin and insulin stimulate lipoprotein-lipase activity and ac (mas) celerate chylomicron degradation. Aim: To report five patients with acute pancreatitis treated with heparin and insulin. Patients and methods: Five patients (4 females and 1 male) seen in the last two years, who suffered acute pancreatitis induced by hypertriglyceridemia are reported. Initial blood triglyceride levels were above 1,000 mg/dl (range 1,590-8,690 mg/dl). Besides the usual treatment of acute pancreatitis, heparin and/or insulin were administered intravenously in continuous infusion. Heparin dose was guided by usual parameters of blood coagulation, and insulin dose, by serial determinations of blood glucose. Pancreatic necrosis was demonstrated in 4 patients. Results: Serum triglyceride levels decreased to

Scientific Electronic Library Online (Spanish)